VU6012962
规格
| Cas Number | 2313526-86-0 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 125 mg/mL (278.77 mM; Need ultrasonic) |
| 过滤标签 | mGluR,GPCR/G Protein,神经元信号传导 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | VU6012962 是一种可口服的中枢神经系统穿透性代谢谷氨酸受体 7 负异位调节剂（mGlu 7 NAM），其 IC 50 为 347 nM。 |
| 英文描述 |
VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator ( mGlu 7 NAM) with an IC 50 of 347 nM In Vitro VU6012962 is highly selective for mGlu7 versus the other seven mGlu receptor subtypes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo VU6012962 (1-10 mg/kg; i.p. injection; 60 minutes prior to testing) decreases anxiety in the elevated zero maze (EZM) assay in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57Bl/6J male mice (8 weeks old) Dosage: 1, 3, and 10 mg/kg Administration: I.p. injections; 60 minutes prior to testing Result: Increased total time spent in the open arms at a dose of 3 mg/kg. 10 mg/kg did cause a decrease in overall locomotion. Form:Solid IC50& Target:mGlu7 347 nM (IC 50 ) |